TESTING -ON Post-Trial ObservatioNal Cohort Study
ESRD | Kidney Diseases | IgA Nephropathy | GlomerulonephritisThe primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose (full-dose vs reduced-dose), ethnicity (Chinese vs other) and kidney function (eGFR above and below 60 mL/min/1.73m2).
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
18 and up
Critères de participation
Inclusion Criteria:
1) Only participants who were randomised into the TESTING trial
Exclusion Criteria
1. Participants who have reached kidney failure requiring maintenance dialysis or kidney transplantation during the TESTING trial
2. Participants who died during the TESTING trial
3. Participants who had withdrawn their consent during the TESTING trial
4. Participants who are unable to provide consent for some other reason
Lieu de l'étude
St Pauls Hospital
St Pauls HospitalVancouver, British Columbia
Canada
Contactez l'équipe d'étude
Toronto General Hospital,
Toronto General Hospital,Toronto, Ontario
Canada
Contactez l'équipe d'étude
University of Alberta Hospitals
University of Alberta HospitalsEdmonton, Alberta
Canada
Contactez l'équipe d'étude
Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences CentreToronto, Ontario
Canada
Contactez l'équipe d'étude
St. Joseph's Healthcare
St. Joseph's HealthcareHamiliton, Ontario
Canada
Contactez l'équipe d'étude
Hôpital Maisonneuve-Rosemont
Hôpital Maisonneuve-RosemontMontreal, Quebec
Canada
Contactez l'équipe d'étude
University of Calgary/Alberta Health Services
University of Calgary/Alberta Health ServicesCalgary, Alberta
Canada
Contactez l'équipe d'étude
London Health Sciences Centre
London Health Sciences CentreLondon, Ontario
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- The George Institute
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT05434325